I didn’t think cough syrups even worked against coughs, but one new paper suggests that bromhexine in common cough syrups reduces both Covid-19 rates of ICU and of mortality.
The era of antivirals has come, not that Big Pharma want you to know that cheap out-of-patent drugs might help. But for years we were told that medical science didn’t have an answer to viruses.
Bromhexine was patented in 1961 and is commonly found in OTC pharmacy cough syrups with names like Bisolvon, Robitussin, and Duro-Tuss (Wiki has a long list).
Theoretically Bromhexine sabotages one of our molecules — with the snappy name of TMPRSS2 (which is shorter than saying Transmembrane protease S2). A protease is a fancy pair of molecular scissors, it chops or tweaks the viral spike and if that doesn’t happen, the virus can’t get into the cell (at least not through it’s favourite path).
The nice thing about an antiviral acting against our molecules is that it’s harder for the virus to mutate to get around it. That means it’s less likely the virus can develop resistance. The downside of targeting our own molecules is that it might fritz things up. Presumably this protease does something useful […]Rating: 0.0/10 (0 votes cast)
September 1, 2020 at 12:17PM